Liu, Chen-Hua <br/><br/>
Real-world effectiveness and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir with or without ribavirin for patients with chronic hepatitis C virus genotype 1b infection in Taiwan.  [electronic resource] 

 -  Journal of gastroenterology and hepatology  Mar 2018 
 - 710-717 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1440-1746 
<br/><br/><label>Standard No.: </label>10.1111/jgh.13912  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>2-Naphthylamine<br/>Aged<br/>Aged, 80 and over<br/>Anilides--administration & dosage<br/>Antiviral Agents--administration & dosage<br/>Carbamates--administration & dosage<br/>Cyclopropanes<br/>Drug Therapy, Combination<br/>Female<br/>Genotype<br/>Hepacivirus--genetics<br/>Hepatitis C, Chronic--drug therapy<br/>Humans<br/>Lactams, Macrocyclic<br/>Macrocyclic Compounds--administration & dosage<br/>Male<br/>Middle Aged<br/>Proline--analogs & derivatives<br/>Retrospective Studies<br/>Ribavirin--administration & dosage<br/>Ritonavir--administration & dosage<br/>Safety<br/>Sulfonamides--administration & dosage<br/>Taiwan<br/>Treatment Outcome<br/>Uracil--administration & dosage<br/>Valine<br/>Viral Load